EXCITING DEVELOPMENT! A UNIVERSAL vaccine called GLA-3M-052-LS+OVA has been created by researchers at Stanford University. It guards against a broad spectrum of respiratory viruses, bacteria AND even allergens. Administered intranasally, this vaccine offers extensive protection within the lungs for several MONTHS.
Goodbye to seasonal viruses as we know them: the first universal vaccine against respiratory infections and allergies is now closer than ever
A universal nasal vaccine that might shield against respiratory viruses, bacteria and even allergies is moving closer to reality, according to scientists
www.ecoticias.com
Goodbye to seasonal viruses as we know them: the first universal vaccine against respiratory infections and allergies is now closer than ever
A universal nasal vaccine that might shield against respiratory viruses, bacteria and even allergies is moving closer to reality, according to scientists
www.ecoticias.com
For more than 230 years, most vaccines have followed the same basic rule. They teach the immune system to recognize a specific antigen, which works well when the target stays relatively stable, but it becomes more complicated when viruses like influenza
Click to expand...
Stanford’s experimental formula, called GLA-3M-052-LS+OVA, takes a different path. It combines molecules that stimulate Toll-like receptors 4 and 7/8 with ovalbumin, a harmless egg protein, so the vaccine can mimic immune “danger signals” and draw T cells into the lungs. In practical terms, the goal is to keep broad local defenses switched on longer, right where many infections first gain a foothold.
What the mouse results actually showed
In the mouse experiments, the vaccine was delivered through the nose, and some animals received multiple doses one week apart. After three doses, mice were protected against [the flu] and other viruses for at least three months, and the amount of virus in their lungs fell by about 700-fold compared with unvaccinated animals.
Click to expand...